Cargando…
Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
BACKGROUND/AIMS: Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with es...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Neurogastroenterology and Motility
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837551/ https://www.ncbi.nlm.nih.gov/pubmed/36581325 http://dx.doi.org/10.5056/jnm22104 |
_version_ | 1784869105505927168 |
---|---|
author | Kim, Joon Sung Seo, Seung In Kang, Sun Hyung Lee, Sang Kil Kim, Ah Rong Park, Hyun Wook Kim, Bong Tae Song, Geun Seog |
author_facet | Kim, Joon Sung Seo, Seung In Kang, Sun Hyung Lee, Sang Kil Kim, Ah Rong Park, Hyun Wook Kim, Bong Tae Song, Geun Seog |
author_sort | Kim, Joon Sung |
collection | PubMed |
description | BACKGROUND/AIMS: Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with esomeprazole in relieving nighttime heartburn and sleep disturbances. METHODS: Patients with erosive esophagitis, nighttime heartburn, and sleep disturbances were randomized to receive tegoprazan 50 mg or esomeprazole 40 mg for 2 weeks. The primary endpoint was time to first nighttime heartburn-free interval. The percentage of nighttime heartburn-free days was also compared between the 2 groups. RESULTS: A total of 46 patients were enrolled in this study. Time to the first nighttime heartburn-free interval was shorter with tegoprazan than with esomeprazole but the difference was not statistically significant (1.5 days vs 3 days, P = 0.151). The percentage of nighttime heartburn-free days was higher in the tegoprazan group but the difference was insignificant (57.8% vs 43.1%, P = 0.107). Adverse events occurred in 2 patients. They were mild in severity. CONCLUSIONS: Tegoprazan may induce faster relief of nighttime heartburn symptoms and may improve sleep disorders associated with nighttime heartburn. Further large-scale studies are required to validate our findings. |
format | Online Article Text |
id | pubmed-9837551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Society of Neurogastroenterology and Motility |
record_format | MEDLINE/PubMed |
spelling | pubmed-98375512023-01-30 Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial Kim, Joon Sung Seo, Seung In Kang, Sun Hyung Lee, Sang Kil Kim, Ah Rong Park, Hyun Wook Kim, Bong Tae Song, Geun Seog J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with esomeprazole in relieving nighttime heartburn and sleep disturbances. METHODS: Patients with erosive esophagitis, nighttime heartburn, and sleep disturbances were randomized to receive tegoprazan 50 mg or esomeprazole 40 mg for 2 weeks. The primary endpoint was time to first nighttime heartburn-free interval. The percentage of nighttime heartburn-free days was also compared between the 2 groups. RESULTS: A total of 46 patients were enrolled in this study. Time to the first nighttime heartburn-free interval was shorter with tegoprazan than with esomeprazole but the difference was not statistically significant (1.5 days vs 3 days, P = 0.151). The percentage of nighttime heartburn-free days was higher in the tegoprazan group but the difference was insignificant (57.8% vs 43.1%, P = 0.107). Adverse events occurred in 2 patients. They were mild in severity. CONCLUSIONS: Tegoprazan may induce faster relief of nighttime heartburn symptoms and may improve sleep disorders associated with nighttime heartburn. Further large-scale studies are required to validate our findings. The Korean Society of Neurogastroenterology and Motility 2023-01-30 2023-01-30 /pmc/articles/PMC9837551/ /pubmed/36581325 http://dx.doi.org/10.5056/jnm22104 Text en © 2023 The Korean Society of Neurogastroenterology and Motility https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Joon Sung Seo, Seung In Kang, Sun Hyung Lee, Sang Kil Kim, Ah Rong Park, Hyun Wook Kim, Bong Tae Song, Geun Seog Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial |
title | Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial |
title_full | Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial |
title_fullStr | Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial |
title_full_unstemmed | Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial |
title_short | Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial |
title_sort | effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837551/ https://www.ncbi.nlm.nih.gov/pubmed/36581325 http://dx.doi.org/10.5056/jnm22104 |
work_keys_str_mv | AT kimjoonsung effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial AT seoseungin effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial AT kangsunhyung effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial AT leesangkil effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial AT kimahrong effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial AT parkhyunwook effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial AT kimbongtae effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial AT songgeunseog effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial |